抗纤维化治疗对特发性肺纤维化死亡率和急性加重的影响:系统评价与荟萃分析
该系统评价与荟萃分析纳入26项研究共12956例特发性肺纤维化(IPF)患者,评估抗纤维化治疗对全因死亡率和急性加重(AE)风险的影响。结果显示抗纤维化治疗与全因死亡率降低相关(汇总RR 0.55,95%CI 0.45-0.66),并与AE风险降低相关(汇总RR 0.63,95%CI 0.53-0.76)。
要点
- 抗纤维化治疗与IPF患者全因死亡率降低相关,汇总RR为0.55。
- 抗纤维化治疗与IPF患者急性加重风险降低相关,汇总RR为0.63。
- AE风险降低在研究类型和尼达尼布亚组中一致,但吡非尼酮亚组不一致。
核心结论
- 抗纤维化治疗可能降低IPF患者全因死亡率和急性加重风险。
研究设计与样本
- 系统评价与荟萃分析,纳入26项研究(8项随机对照试验和18项队列研究),共12956例IPF患者。
- 检索数据库包括Ovid MEDLINE、Ovid Embase、Ovid Cochrane Central Register of Controlled Trials、Ovid Cochrane Database of Systematic Reviews和Scopus。
- 纳入比较IPF患者接受与未接受抗纤维化治疗的死亡或AE事件原始研究。
- 采用随机效应荟萃分析(逆方差法)合并相对风险(RR)及95%CI。
主要发现
- 抗纤维化治疗与全因死亡率降低相关,汇总RR为0.55(95%CI 0.45-0.66),I2为82%。
- 抗纤维化治疗与AE风险降低相关,汇总RR为0.63(95%CI 0.53-0.76),I2为0%。
- 全因死亡率效应在研究类型、偏倚风险、随访时长和抗纤维化药物亚组分析中一致。
- AE风险效应在研究类型和尼达尼布亚组分析中一致,但在吡非尼酮亚组中不一致。
临床怎么用
- 对于IPF患者,抗纤维化治疗(尼达尼布或吡非尼酮)可考虑用于降低死亡和急性加重风险。
局限性
- 全因死亡率合并分析存在较大异质性(I2=82%)。
- AE风险降低在吡非尼酮亚组中不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are two antifibrotic medications currently approved for slowing the rate of lung function decline in IPF, but data on treatment effect on mortality and risk of acute exacerbation (AE) remains limited or unknown. RESEARCH QUESTION: Does antifibrotic treatment decrease risk of mortality and AE? STUDY DESIGN AND METHODS: A comprehensive search of several databases, including Ovid MEDLINE(R), Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus, was conducted. Studies were included if they were original articles comparing mortality or AE events in IPF patients with and without antifibrotic treatment. Relative risk (RR) with 95%CI was pooled using random-effects meta-analyses with inverse variance method, assessing two primary outcomes of all-cause mortality and AE risk. RESULTS: A total of 12,956 patients across 26 studies (eight randomized controlled trials and 18 cohort studies) were included in the meta-analysis. Antifibrotic treatment was associated with decreased risk of all-cause mortality with a pooled RR of 0.55 (95% CI, 0.45-0.66) and I2 of 82%. This effect was consistent across additional subgroup analyses, including stratification by study type, risk of bias, duration of follow-up, and antifibrotic subtype. Antifibrotic treatment also reduced the risk of AE, with a pooled RR of 0.63 (95% CI, 0.53-0.76), and I2 of 0%. Effect on AE risk was consistent across subgroup analyses by study type and for nintedanib but not for pirfenidone. INTERPRETATION: Antifibrotic treatment appears to reduce the risk of all-cause mortality and AE in IPF. Despite greater heterogeneity with pooled analysis, its effect was robust in subgroup analyses by study type, duration of follow-up, and antifibrotic subtype.
引用
- Petnak T, Lertjitbanjong P, Thongprayoon C, et al. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest. 2021. PMID: 34217681. doi:10.1016/j.chest.2021.06.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。